ABSTRACT
INTRODUCTION
Many astronauts experience difficulty sleeping during spaceflight.' Because sleep deprivation affects performance and can cause other medical and operational problems, the in-flight use of sedative-hypnotics as sleeping aids is common. 4 Two hypnotics, temazepam (Restoril, a benzodiazepine) and zolpidem (Ambien, an imidazopyridine), are used by astronauts during their missions, including the night prior to shuttle landings.
Some sedative-hypnotics have side effects that affect the cardiovascular system by decreasing arterial blood pressure and increasing heart rate. 5 After spaceflight, astronauts experience orthostatic hypotension 68 due to, among other things,-reduction of plasma volume and autonomic dysfunction. It is possible that the use of these hypnotics is an additional contributor. Temazepam belongs to the benzodiazepine family that causes sedation, hypnosis, decreased anxiety, muscle relaxation, anterograde amnesia, and anticonvulsant activity. 9 Zolpidem is an imidazopyridine that differs structurally from the benzodiazepines.'° It has sedative-hypnotic properties, but has only minor anxiolytic and anticonvulsant properties, and no myorelaxant 1l2 Although the National Aeronautics and Space Administration (NASA) began using temazepam and zolpidem as 5 inflight sleeping aids in 1990 and 1994, respectively, the ettects ot these medications on cardiovascular responses to upright posture have not been documented. Therefore, the purpose of this study was to assess whether hypnotics exacerbate orthostatic intolerance in astronauts on landing day.
METHODS
This study was conducted in two parts. The first part was a prospective study in laboratory volunteers on the effects of temazepam on cardiovascular responses to standing. Based on those results, a retrospective analysis was performed on astronauts' preflight stand test, and postflight stand tests with and without the influence of temazepam or zolpidem.
Subjects. The NASA Johnson Space Center Committee for the Protection at Human
Subjects approved these protocols. There were two sets of subjects: astronauts and nonastronauts.
Ground-based Study. All subjects (non-astronauts) had passed an Air Force Class III physical exam before their participation and signed written informed consent. Ten subjects were studied before and ten hours after a single, 30 mg oral dose of temazepam.
Subjects abstained from caffeine, alcohol, and any medications for 12 hours prior to each study and ate a.light breakfast before reporting to the laboratory. Testing on the first day began at 8 AM. After the test session, subjects were given 30 mg of temazepam which they ingested orally at 10 PM that night. They were studied again at 8 AM the following morning, ten hours after taking the drug. For each test, subjects were placed on a bed in a quiet, air-conditioned room where the temperature was 23-25 °C. After 20 minutes of supine rest, baseline arterial blood pressure and heart rate were recorded. Then a tightly sealing Silastic chamber, connected to a computer-controlled bellows, was strapped to the anterior neck.' 3 During held expiration, and triggered by successive R-waves, the pressure in the neck chamber was increased to +40 mmHg for four heart beats and then Data Analysis -Stand Tests. The stand portion of the test assessed the systolic and diastolic blood pressures and heart rates pre-and post-temazepam and zolpidem. Both systolic and diastolic blood pressures and heart rates were measured every minute for six minutes supine and ten minutes standing. Systolic and diastolic blood pressures and heart rates were stable in the supine position, so only the last supine measurement was reported.
Statistics. All data are presented as mean ± SE. A Kruskal-Walljs one-way analysis of variance (ANOVA) on Ranks was used for between groups comparison (i.e. control group vs. temazepam or zolpidem group). A paired t-test was used for within-group comparisons (i.e. pre-vs. post-temazepam). For all tests, significance was set at P < 0.05.
RESULTS
The anthropometric data for all subjects are presented in Table 1 . Age, body weight, and height did not differ significantly among any of the groups. Between January 1990
and December 1996, 13.7% of astronauts took temazepam and 4.6% took zolpidem during flight. Therefore, astronauts took temazepam three times more than zolpidem during this period.
Ground-based Results. In non-astronauts, one subject who had not become presyncopal before taking temazepam became presyncopal during standing after taking it.
Two additional subjects reported feeling lightheaded and dizzy the morning after taking temazepam but before reporting to the laboratory. These two subjects did not become presyncopal during their stand tests. Fig. I shows that finger arterial blood pressures and heart rates decreased in the subject who became presyncopal after taking temazepam.
Before temazepam (upper panel), arterial systolic blood pressure was maintained the entire time of standing. After temazepam, systolic blood pressure dropped to 70 mmHg (bottom panel) and the subject became presyncopal. Standing heart rate post-temazepam was 15 bpm higher than pre-temazepam until presyncope occurred. Fig. 2 represents supine and standing arterial blood pressures and heart rates before and after 30 mg of temazepam in the ground-based subjects. As a group, there was no effect of temazepam on supine or standing arterial blood pressures. Supine heart rates were not different after temazepam, but standing heart rates were significantly higher (P
•< 0.05).
Carotid Baroreceptor Reflex Test. Carotid baroreceptor-cardjac reflex responses before and after temazepam are shown in Fig. 3 and Table 2 . Temazepam resulted in no change in slope, range, or operational point, but caused a significant shift on the R-R interval axis which paralleled the increase in heart rate.
Flight-based Results. Fig. 4 depicts supine and standing systolic and diastolic blood pressures and heart rates for the subjects who took temazepam the night before landing and those who did not. No astronaut took any drug preflight. Before flight (Fig. 4 left) , supine and standing blood pressures and heart rates were not different between groups, although blood pressures were somewhat lower in the temazepam group. On landing day (Fig. 4 right) , supine blood pressures were higher than preflight in both groups, but those who had taken temazepam had very dramatic falls in systolic blood pressure with standing that were significantly greater than in those who had not taken the drug (P < 0.05). There were no intergroup differences in supine or standing heart rates before 12 flight, however on landing day, the temazepam group had significantly higher standing heart rates than those who did not take the drug. Therefore, zolpidem is probably eliminated by the time of landing. In addition, there also are differences in the mechanisms of actions between the two drugs.
In the initial study, the ground-based subjects did not, as a group, experience low blood pressure during standing after temazeparn, but they did have significantly higher standing heart rates. These findings were not unexpected. Several studies have shown that temazepam does not affect arterial blood pressure, yet can cause significant increases in heart rate during sitting, 5 standing5 and lower body negative pressure' 5 . However, one subject did become presyncopal after taking temazepam, and two additional subjects reported incidents of dizziness and hypotension after taking the drug.
In the retrospective analysis of the astronaut stand tests, temazepam was associated with significant falls in standing systolic blood pressure after spaceflight (Fig. 4) . In fact, their hemodynamic responses to upright posture fell within the range of clinical orthostatic hypotension: systolic blood pressure falls greater than 20 mmHg and/or heart rate increases greater than 27 beats per minute 6 Thus, it is clear that temazepam has hemodynamic effects which are significantly exaggerated when combined with the effects of spaceflight itself.
Temazepam, a benzodiazepine, binds non-selectively to all three subtypes of the benzodiazepine receptor (BZ1, BZ2, and BZ3). Thus, in addition to BZ1 sedative effects, benzodiazepine also has BZ2, and BZ3's anticonvulsant, myorelaxant, and anxiolytic Each value shows mean ± SE. * P <0.05 vs. pre-temazepam. There were no differences between zolpidem and control groups. The values are from two curves of R-R interval with carotid distending pressure in Fig.2 (means ± SE). 
